AOD-9604 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
AOD-9604 (Fragment 177-191 of Human Growth Hormone (modified)) is researched primarily for fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation. The only GH fragment that selectively targets fat loss without any of growth hormone's effects on blood sugar, insulin, or IGF-1 — making it metabolically clean. The catch is that human efficacy was modest compared to impressive animal data. It belongs to the Lipolytic peptide, GH fragment analog category of compounds.
What Is AOD-9604?
AOD-9604 (Fragment 177-191 of Human Growth Hormone (modified)) is a Lipolytic peptide, GH fragment analog. Synthetic analog of human GH fragment 177-191, engineered to selectively activate lipolysis without systemic GH effects.
The only GH fragment that selectively targets fat loss without any of growth hormone's effects on blood sugar, insulin, or IGF-1 — making it metabolically clean. The catch is that human efficacy was modest compared to impressive animal data. It has attracted significant research interest for its potential effects on fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation.
How Does AOD-9604 Produce These Benefits?
Activates beta-3 adrenergic receptors in adipose tissue, triggering cAMP-mediated lipolysis and release of stored fat for energy. Suppresses lipogenesis (new fat formation) while promoting fat breakdown. Unlike full growth hormone, it does not raise IGF-1 or impact glucose metabolism, blood sugar, or insulin sensitivity.
This multi-pathway activity is why AOD-9604 shows potential across several different applications rather than being limited to a single use case.
Can AOD-9604 Help With Fat Loss?
Research suggests AOD-9604 may support fat loss through its lipolytic peptide, gh fragment analog activity. 12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects.
Protocols targeting fat loss typically use 250-1000 mcg daily administered once daily, ideally morning fasted for 12-24 weeks.
Can AOD-9604 Help With Increased Fat Oxidation?
Research suggests AOD-9604 may support increased fat oxidation through its lipolytic peptide, gh fragment analog activity. 12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects.
Protocols targeting increased fat oxidation typically use 250-1000 mcg daily administered once daily, ideally morning fasted for 12-24 weeks.
Can AOD-9604 Help With Improved Body Composition?
Research suggests AOD-9604 may support improved body composition through its lipolytic peptide, gh fragment analog activity. 12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects.
Protocols targeting improved body composition typically use 250-1000 mcg daily administered once daily, ideally morning fasted for 12-24 weeks.
Can AOD-9604 Help With Joint Health Support?
Research suggests AOD-9604 may support joint health support through its lipolytic peptide, gh fragment analog activity. 12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects.
Protocols targeting joint health support typically use 250-1000 mcg daily administered once daily, ideally morning fasted for 12-24 weeks.
Can AOD-9604 Help With No Igf-1 Elevation?
Research suggests AOD-9604 may support no IGF-1 elevation through its lipolytic peptide, gh fragment analog activity. 12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects.
Protocols targeting no IGF-1 elevation typically use 250-1000 mcg daily administered once daily, ideally morning fasted for 12-24 weeks.
Can Stacking Enhance AOD-9604 Benefits?
Pairs with CJC-1295/Ipamorelin for enhanced body composition (AOD handles fat loss while GH peptides handle lean mass). Also complements fasting and HIIT training protocols.
See our AOD-9604 stacking guide for detailed combination protocols.
What Is the Bottom Line on AOD-9604 Benefits?
AOD-9604 is researched for fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation. The evidence base includes: 12-week RCT showed 2.6 kg weight loss vs 0.8 kg placebo. However, a larger 24-week Phase III trial (536 subjects) failed to demonstrate significant weight loss, leading to development discontinuation in 2007. Six controlled trials established tolerability across 900+ subjects.
AOD-9604 is not fda-approved. development discontinued 2007. available as research chemical. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
AOD-9604: The Fat Loss Peptide Fragment
Related Reading
- AOD-9604 Dosage Guide
- AOD-9604 Side Effects
- AOD-9604 Stacking Guide
- AOD-9604 Cycle Guide
- AOD-9604 Research
- CJC-1295 Complete Guide
Calculate Your AOD-9604 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for AOD-9604.
Open Calculator →Research-Grade Sourcing
If you're going to research AOD-9604, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 (Fragment 177-191 of Human Growth Hormone (modified)) is a Lipolytic peptide, GH fragment analog. Synthetic analog of human GH fragment 177-191, engineered to selectively activate lipolysis without systemic GH effects. It is researched for fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation.
What is the recommended AOD-9604 dosage?
Common dosages: 250-1000 mcg daily administered once daily, ideally morning fasted via subcutaneous injection. Cycle length: 12-24 weeks. Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of AOD-9604?
Well-tolerated across 900+ participants in clinical trials. Minimal adverse effects — potential mild headache, dizziness, or injection site reactions. One of the safest peptides in terms of documented human tolerability.
Is AOD-9604 safe?
AOD-9604 has shown a favorable safety profile in research. Not FDA-approved. Development discontinued 2007. Available as research chemical. All research should follow appropriate safety protocols.